Vietnam Conjunctivitis Therapeutics Market Report 2022 to 2030

Vietnam Conjunctivitis Therapeutics Market Analysis

$ 3999

The Vietnam Conjunctivitis Therapeutics Market was valued at $21 Mn in 2022 and is predicted to grow at a CAGR of 5.63% from 2023 to 2030, to $32 Mn by 2030. The key drivers of this industry include the increasing prevalence of conjunctivitis, expanding healthcare infrastructure, and increasing treatment options. The industry is primarily dominated by players such as Allergan, Bausch & Lomb, Novartis, Rohto, Santen, Pfizer, and Mentholatum among others.

CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Riddhi Solanki

Buy Now

Vietnam Conjunctivitis Therapeutics Market Analysis Executive Summary

The Vietnam Conjunctivitis Therapeutics Market is at around $21 Mn in 2022 and is projected to reach $32 Mn in 2030, exhibiting a CAGR of 5.63% during the forecast period.

Conjunctivitis, commonly known as pink eye, is the inflammation of the conjunctiva, a transparent membrane covering the surface of the eye and the eyelid. It can be caused by various factors, including viral or bacterial infections, allergic reactions, irritants, and exposure to chemicals. Conjunctivitis symptoms include redness, irritation, excessive tearing, and, in some cases, a gritty sensation or mucus discharge. Allergic conjunctivitis is commonly treated with nonsteroidal anti-inflammatory drugs, antihistamines, or topical steroid eye drops. Infectious conjunctivitis, particularly the bacterial type, is typically treated with antibiotic eye drops or ointments. Leading manufacturers of these therapy alternatives include Pfizer, Sanofi, Alcon, and Allergan.

Vietnam faces a significant burden of infectious conjunctivitis which affects more than 30% of the adult population. Market expansion is propelled by significant factors such as the increase in the burden of conjunctivitis, expanding healthcare infrastructure, and increasing treatment options. However, conditions such as high costs of treatments, lack of resources, and market saturation restrict the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Increasing burden of conjunctivitis: More than 30% of the Vietnamese adult population is affected by viral conjunctivitis. Air pollution and poor hygiene contribute to conjunctivitis causative agents. Vietnam is experiencing increased urbanization and exposure to digital services increasing susceptibility to conjunctivitis risks. Additionally, the aging population has a higher risk of conjunctivitis, contributing to market growth.

Expanding healthcare infrastructure: The Vietnamese government is investing significantly in healthcare infrastructure, including developing new hospitals and clinics. This effort attempts to improve access to diagnosis and treatment. Also, the growing private healthcare sector offers more treatment options and specific therapies for eye diseases.

Expanding treatment options: Pharmaceutical companies are researching new conjunctivitis therapies, including targeted therapy with fewer adverse effects. The advent of innovative treatment options, including combination medications and sustained-release products, has increased adoption from both patients and healthcare professionals, expanding the market.

Market Restraints

Lack of resources: Disparities in access to conjunctivitis treatment arise due to an unequal distribution of healthcare facilities, especially in rural areas. A shortage of skilled ophthalmologists and optometrists in rural areas hinders quick and accurate diagnosis and treatment. Many Vietnamese citizens, from low-income families, have additional financial constraints owing to limited healthcare insurance coverage.

High costs of treatments: A considerable portion of the Vietnamese population finds the cost of branded conjunctivitis drugs as a financial constraint. The scarcity and cost of generic alternatives restrict access to appropriate treatment. This results in high out-of-pocket expenditures for this population due to limited insurance coverage.

Market saturation: Existence of reputable domestic and global firms with robust brand visibility and a significant market presence. Traditional and alternative therapies are being adopted for the treatment of conjunctivitis which limits the market for prescription drugs

Healthcare Policies and Regulatory Landscape

Vietnam's major regulatory organization for medications and pharmaceuticals is the Ministry of Health (MOH), notably the Drug Administration of Vietnam (DAV). The DAV regulates and controls the quality, safety, and efficacy of pharmaceutical products in the country.

To obtain licensure for drugs and pharmaceuticals in Vietnam, manufacturers and distributors must undergo a rigorous registration process with the DAV. The DAV conducts a thorough evaluation of the submitted data to ensure compliance with Vietnamese regulations and standards. Once a product is approved, a license is issued, allowing it to be marketed and sold in Vietnam.

The regulatory environment for new entrants into the pharmaceutical sector in Vietnam is strict, requiring adherence to quality and safety standards. Companies entering the market should maintain rigorous regulatory procedures while demonstrating the safety and efficacy of their products through clinical testing and documentation.

Competitive Landscape

Key Players

Allergan
Alembic Pharmaceuticals
Bausch & Lomb
Novartis
Mentholatum Company
Sanofi
Pfizer
Abbott Laboratories
Rohto Pharmaceuticals
Santen Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Vietnam Conjunctivitis Therapeutics Market Segmentation

By Drug Class

Antibiotics
Antiviral
Antiallergic
Others

By Treatment

Mast Cell Stabilizers
Decongestant
Immunotherapy
Antihistamines
Non-steroidal anti-inflammatory drugs
Olopatadine
Epinastine
Others

By Disease Type

Bacterial
Chemical
Viral
Allergic

By Formulation

Ointment
Drops
Drugs

By End Users

Hospitals and clinics
Online Pharmacies
Retail Pharmacies
Drug Stores

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.